AU2340397A - Use of nicotine to treat liver disease - Google Patents

Use of nicotine to treat liver disease

Info

Publication number
AU2340397A
AU2340397A AU23403/97A AU2340397A AU2340397A AU 2340397 A AU2340397 A AU 2340397A AU 23403/97 A AU23403/97 A AU 23403/97A AU 2340397 A AU2340397 A AU 2340397A AU 2340397 A AU2340397 A AU 2340397A
Authority
AU
Australia
Prior art keywords
nicotine
liver disease
treat liver
treat
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23403/97A
Inventor
Keith D. Lindor
William J. Sandborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2340397A publication Critical patent/AU2340397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU23403/97A 1996-03-21 1997-03-21 Use of nicotine to treat liver disease Abandoned AU2340397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63251396A 1996-03-21 1996-03-21
US08632513 1996-03-21
PCT/US1997/004601 WO1997034605A1 (en) 1996-03-21 1997-03-21 Use of nicotine to treat liver disease

Publications (1)

Publication Number Publication Date
AU2340397A true AU2340397A (en) 1997-10-10

Family

ID=24535808

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23403/97A Abandoned AU2340397A (en) 1996-03-21 1997-03-21 Use of nicotine to treat liver disease

Country Status (2)

Country Link
AU (1) AU2340397A (en)
WO (1) WO1997034605A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2380052C (en) * 1999-07-28 2007-10-23 John Cooke Nicotine receptor agonists in stem cell and progenitor cell recruitment
US7838539B2 (en) 1999-07-28 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DK1202736T3 (en) 1999-07-28 2008-12-15 Univ Leland Stanford Junior Nicotine in therapeutic angiogenesis and vasculogenesis
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
US7718677B2 (en) 2007-04-02 2010-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst Compositions and methods for treatment of symptoms in parkinson's disease patients
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
JP2018511355A (en) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Drug delivery method and system
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Device and method for transdermal drug delivery
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
CN115581697A (en) * 2022-10-19 2023-01-10 云南中烟工业有限责任公司 Application of nicotine and derivatives as FXR-meglin/cublin regulator in preparation of choleretic products

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639418A1 (en) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen NICOTINE-BASED AGENT
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5414005A (en) * 1993-10-28 1995-05-09 Dynagen, Inc. Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
MA23587A1 (en) * 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME
AU2702795A (en) * 1994-06-23 1996-01-19 Procter & Gamble Company, The Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
AU5092696A (en) * 1995-03-17 1996-10-08 Lectec Corporation Treatment of inflammatory bowel disorders with cotinine

Also Published As

Publication number Publication date
WO1997034605A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
AU7698698A (en) Methods and compositions for targeting compounds to muscle
AU2557397A (en) Removal of tissue
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
AU4067697A (en) Therapeutic compositions for treatment of cancer
AU2340397A (en) Use of nicotine to treat liver disease
AU1773600A (en) Topical treatment of skin disease
AU3107197A (en) Medicinal compositions for treating liver diseases
AU3784999A (en) Methods for treatment of pain
AU2058697A (en) Treatment of sleep disorders
AU5083098A (en) Use of leptin to stimulate hematopoiesis
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU2036297A (en) Topical formulations of aciclovir
AU2821295A (en) Compositions and methods for the treatment of tumors
AU2969597A (en) Treatment of vascular lesions
PL327732A1 (en) Compounds of therapeutic activity
AU4704797A (en) Use of benzopyranols to treat neurological disorders
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU5425098A (en) Compounds and methods to treat infectious diseases
AU2193797A (en) Delivery of therapeutic agents to the prostate
AU2500997A (en) Use of prostaglandins to treat ataxia telangiectasia
AU7622798A (en) Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU1931895A (en) Treatment of graft-versus-host disease
AU8760298A (en) Coup-tfi directed therapies in the treatment of disease